RecruitingNot ApplicableNCT04592445

Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having HFpEF

Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having Heart Failure With Preserved Ejection Fraction: Randomized Controlled Feasibility Trial - The Rebalance HF Study


Sponsor

Axon Therapies, Inc.

Enrollment

150 participants

Start Date

Dec 18, 2020

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this clinical study is to evaluate the safety and early effectiveness of a catheter-based procedure that treats a nerve called the right greater splanchnic nerve. The study includes people who have heart failure with preserved ejection fraction (HFpEF). The goal is to learn whether this procedure, performed using the Satera Ablation System, may help improve symptoms and to better understand which patients may benefit most from this treatment in the future.


Eligibility

Min Age: 40 Years

Plain Language Summary

Simplified for easier understanding

This study tests whether destroying a specific nerve (the right greater splanchnic nerve) using a minimally invasive procedure can relieve symptoms in people with a type of heart failure where the heart pumps normally but is too stiff — called HFpEF (heart failure with preserved ejection fraction). The nerve being targeted helps regulate blood pressure in the chest and abdomen. **You may be eligible if...** - You have been diagnosed with HFpEF - You have been on diuretics (water pills) for at least 30 days for heart failure - You have had at least one heart failure hospitalization in the past year or your blood markers of heart strain are elevated - You are on stable heart failure medications **You may NOT be eligible if...** - You have a different type of heart failure (reduced ejection fraction) - You have severe kidney problems - You have had a recent major heart event (heart attack, stroke) in the past 90 days - You have other significant conditions that make this procedure unsafe Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEGreater Splanchnic Nerve Ablation

The greater splanchnic nerve (GSN) ablation procedure begins with a small needle puncture in the groin or neck to access a vein, using methods that are commonly used for heart procedures. Doctors then guide thin tubes and wires through the vein to reach a nerve called the right greater splanchnic nerve. X-ray imaging is used to help the doctor see where the catheter is and guide it to the correct location. Once the catheter is in the right place, the doctor uses the device to treat the nerve using controlled heat.

DEVICESham Control

During the sham procedure, a small needle puncture will be made in the groin or neck to access a vein using standard medical techniques. A short tube will be placed into the vein, similar to what is done for many heart procedures. The Satera catheter and treatment devices will not be inserted, and the nerve will not be treated. The procedure will take about the same amount of time as the treatment procedure.


Locations(20)

Cardiology PC

Birmingham, Alabama, United States

Arizona Cardiovascular Research Center

Phoenix, Arizona, United States

Scripps Health

La Jolla, California, United States

University of California, San Francisco

San Francisco, California, United States

Bluhm Cardiovascular Institute of Northwestern University

Chicago, Illinois, United States

University of Chicago Medical Center

Chicago, Illinois, United States

Prairie Education and Research Cooperative

Springfield, Illinois, United States

Ascension St. Vincent - Cardiovascular Research Institute

Indianapolis, Indiana, United States

Cardiovascular Institute of the South

Houma, Louisiana, United States

Michigan Medicine, University of Michigan

Ann Arbor, Michigan, United States

Mayo Clinic

Rochester, Minnesota, United States

St. Louis Heart and Vascular

St Louis, Missouri, United States

Weill Cornell Medicine

New York, New York, United States

Icahn School of Medicine at Mount Sinai

New York, New York, United States

Columbia University Medical Center

New York, New York, United States

Rochester General Hospital

Rochester, New York, United States

Duke University Medical Center

Durham, North Carolina, United States

Ohio State University Wexner Medical Center

Columbus, Ohio, United States

Medical University of South Carolina

Charleston, South Carolina, United States

Virginia Commonwealth University Medical Center

Richmond, Virginia, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04592445


Related Trials